Description

ARA-290

(Erythropoietin-Derived Peptide – Tissue Protective & Anti-Inflammatory Modulator)

ARA-290 is a synthetic peptide derived from the tertiary structure of the B-helix region of Erythropoietin (EPO). It was engineered to selectively activate tissue-protective signaling pathways associated with the innate repair receptor while avoiding erythropoietic activity. Unlike native erythropoietin, which stimulates red blood cell production through the classical EPO receptor, ARA-290 interacts with the innate repair receptor (IRR) complex composed of the erythropoietin receptor and the CD131 beta common receptor. This selective receptor activation has been investigated in multiple experimental models related to neuropathic pain, inflammation, and tissue injury. Preclinical and early-phase clinical studies have examined ARA-290 for its ability to reduce inflammatory signaling, protect neural tissue, and support cellular repair mechanisms without affecting hematocrit or red blood cell production.

Mechanism of Action

(Based on Preclinical and Early Clinical Research)

Activation of the innate repair receptor (IRR): ARA-290 selectively binds the IRR complex (EPOR-CD131), initiating intracellular signaling associated with tissue protection and repair while avoiding hematopoietic stimulation.

Anti-inflammatory signaling: Demonstrates downregulation of pro-inflammatory cytokines and mediators involved in chronic inflammatory pathways in experimental models.

Neuropathic pain modulation: Research models suggest reduction of neuropathic pain signaling through modulation of neuroimmune interactions and inflammatory mediators in peripheral nerves.

Neuroprotective activity: Investigated for protective effects on neuronal tissue during ischemic or inflammatory injury through activation of cellular survival pathways.

Microvascular and tissue repair support: Studies suggest improved microvascular integrity and enhanced tissue recovery in models of nerve damage and metabolic injury.